The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see ...

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after ...

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

The company's Phase I/II trial of the drug demonstrated a 46.5 percent overall response rate in patients with FGFR2 fusions or rearrangements.

The firm is raising funds through a reserved offering of new shares, which will fund development of two gene therapies for congenital hearing loss.

The firm said it expects to advance development of cell therapies and radioconjugates for cancer, blood disorders, and autoimmune diseases in China.

The company will use the funds to further commercialize its FDA-approved software for sepsis risk assessment, and to integrate precision sepsis diagnostics with personalized therapy.